Hereditary Clotting Factor Deficiencies (Bleeding Disorders)

[1]  M. Manco‐Johnson,et al.  Athletic Participation in Severe Hemophilia: Bleeding and Joint Outcomes in Children on Prophylaxis , 2009, Pediatrics.

[2]  A. Iorio,et al.  Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. , 2009, Blood.

[3]  F. Peyvandi,et al.  Factor V Deficiency , 2009, Seminars in thrombosis and hemostasis.

[4]  R. De Cristofaro,et al.  Congenital prothrombin deficiency. , 2009, Seminars in thrombosis and hemostasis.

[5]  C. Hermans,et al.  Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  L. Almasy,et al.  Inhibitors of factor VIII in black patients with hemophilia. , 2009, The New England journal of medicine.

[7]  T. Kennedy-Martin,et al.  A systematic review of the cost‐effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  S. L. Carpenter,et al.  α2‐Antiplasmin and its deficiency: fibrinolysis out of balance , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  R. Ljung,et al.  Management of carriers and babies with haemophilia , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  P. Mannucci,et al.  Back to the future: a recent history of haemophilia treatment , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  S. Pipe.  Recombinant clotting factors , 2008, Thrombosis and Haemostasis.

[12]  J. Saint-Remy,et al.  The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high‐titre inhibitors: association of clinical outcome with inhibitor epitope profile , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  B. Wiman,et al.  Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[15]  C. Négrier,et al.  Coagulation factor concentrates: past, present, and future , 2007, The Lancet.

[16]  U. Seligsohn,et al.  Factor XI in haemostasis and thrombosis: Past, present and future , 2007, Thrombosis and Haemostasis.

[17]  D. DiMichele.  Immune tolerance: critical issues of factor dose, purity and treatment complications , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  J. Astermark,et al.  Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  E. Berntorp,et al.  The von Willebrand disease prophylaxis network: exploring a treatment concept , 2006, Journal of thrombosis and haemostasis : JTH.